Literature DB >> 25444906

Adeno-associated virus-mediated cancer gene therapy: current status.

Jingfeng Luo1, Yuxuan Luo2, Jihong Sun1, Yurong Zhou1, Yajing Zhang1, Xiaoming Yang3.   

Abstract

Gene therapy is one of the frontiers of modern medicine. Adeno-associated virus (AAV)-mediated gene therapy is becoming a promising approach to treat a variety of diseases and cancers. AAV-mediated cancer gene therapies have rapidly advanced due to their superiority to other gene-carrying vectors, such as the lack of pathogenicity, the ability to transfect both dividing and non-dividing cells, low host immune response, and long-term expression. This article reviews and provides up to date knowledge on AAV-mediated cancer gene therapy. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Adeno-associated virus; Cancer; Cancer gene therapy; Gene vehicle

Mesh：

Year:  2014        PMID： 25444906      PMCID： PMC4259838          DOI： 10.1016/j.canlet.2014.10.045

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  122 in total

1.  Adeno-associated virus-mediated survivin mutant Thr34Ala cooperates with oxaliplatin to inhibit tumor growth and angiogenesis in colon cancer.

Authors:  Zhimou Xue; Ping Hu Sun; Li Ming Zhu; Shi Hu Jiang; Min Min Qiao; Alfred L Chi; Shui Ping Tu
Journal:  Oncol Rep       Date:  2011-01-28       Impact factor: 3.906

2.  Quantitative analysis of the packaging capacity of recombinant adeno-associated virus.

Authors:  J Y Dong; P D Fan; R A Frizzell
Journal:  Hum Gene Ther       Date:  1996-11-10       Impact factor: 5.695

3.  Immunotherapy for SV40 T/t antigen-induced breast cancer by recombinant adeno-associated virus serotype 2 carrying interleukin-15 in mice.

Authors:  Giou-Teng Yiang; Pei-Lun Chou; Hsiu-Feng Tsai; Li-Ann Chen; Wei-Jung Chang; Yung-Luen Yu; Chyou-Wei Wei
Journal:  Int J Mol Med       Date:  2012-02-17       Impact factor: 4.101

4.  MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors.

Authors:  Jayavarshni Ganesan; Deepak Ramanujam; Yassine Sassi; Andrea Ahles; Claudia Jentzsch; Stanislas Werfel; Simon Leierseder; Xavier Loyer; Mauro Giacca; Lorena Zentilin; Thomas Thum; Bernhard Laggerbauer; Stefan Engelhardt
Journal:  Circulation       Date:  2013-04-26       Impact factor: 29.690

5.  Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector.

Authors:  Dolan Sondhi; Neil R Hackett; Daniel A Peterson; Jamie Stratton; Michael Baad; Kelly M Travis; James M Wilson; Ronald G Crystal
Journal:  Mol Ther       Date:  2006-12-19       Impact factor: 11.454

6.  Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2.

Authors:  E A Rutledge; C L Halbert; D W Russell
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

7.  Recombinant adeno-associated virus encoding Epstein-Barr virus latent membrane proteins fused with heat shock protein as a potential vaccine for nasopharyngeal carcinoma.

Authors:  Jianqing Pan; Qin Zhang; Jianfeng Zhou; Ding Ma; Xiao Xiao; Dao Wen Wang
Journal:  Mol Cancer Ther       Date:  2009-09-01       Impact factor: 6.261

8.  AAV-mediated human PEDF inhibits tumor growth and metastasis in murine colorectal peritoneal carcinomatosis model.

Authors:  Qin Jie Wu; Chang Yang Gong; Shun Tao Luo; Dong Mei Zhang; Shuang Zhang; Hua Shan Shi; Lian Lu; Heng Xiu Yan; Sha Sha He; Dan Dan Li; Li Yang; Xia Zhao; Yu Quan Wei
Journal:  BMC Cancer       Date:  2012-03-30       Impact factor: 4.430

9.  Hsp40 gene therapy exerts therapeutic effects on polyglutamine disease mice via a non-cell autonomous mechanism.

Authors:  H Akiko Popiel; Toshihide Takeuchi; Hiromi Fujita; Kazuhiro Yamamoto; Chiyomi Ito; Hiroshi Yamane; Shin-ichi Muramatsu; Tatsushi Toda; Keiji Wada; Yoshitaka Nagai
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

10.  Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial.

Authors:  Robert E MacLaren; Markus Groppe; Alun R Barnard; Charles L Cottriall; Tanya Tolmachova; Len Seymour; K Reed Clark; Matthew J During; Frans P M Cremers; Graeme C M Black; Andrew J Lotery; Susan M Downes; Andrew R Webster; Miguel C Seabra
Journal:  Lancet       Date:  2014-01-16       Impact factor: 79.321
View more
  20 in total

Review 1.  Transcription factor decoy: a pre-transcriptional approach for gene downregulation purpose in cancer.

Authors:  Seyed Mohammad Ali Hosseini Rad; Lida Langroudi; Fatemeh Kouhkan; Laleh Yazdani; Alireza Nouri Koupaee; Sara Asgharpour; Zahra Shojaei; Taravat Bamdad; Ehsan Arefian
Journal:  Tumour Biol       Date:  2015-04-04

2.  Immune effect and safety evaluation of vaccine prepared by dendritic cells modified by rAAV-carrying BCSG1 gene.

Authors:  W-H Wang; C-H Zhou; J Ding; Y-X Zhang; L-L Zheng; S-F Chen; W Zhang
Journal:  Gene Ther       Date:  2016-08-24       Impact factor: 5.250

3.  Enhanced Targeted Gene Transduction: AAV2 Vectors Conjugated to Multiple Aptamers via Reducible Disulfide Linkages.

Authors:  Yuan Wu; Liqin Zhang; Cheng Cui; Sena Cansiz; Hao Liang; Cuichen Wu; I-Ting Teng; Weijun Chen; Yuan Liu; Weijia Hou; Xiaobing Zhang; Weihong Tan
Journal:  J Am Chem Soc       Date:  2017-12-27       Impact factor: 15.419

Review 4.  Novel delivery approaches for cancer therapeutics.

Authors:  Ashim K Mitra; Vibhuti Agrahari; Abhirup Mandal; Kishore Cholkar; Chandramouli Natarajan; Sujay Shah; Mary Joseph; Hoang M Trinh; Ravi Vaishya; Xiaoyan Yang; Yi Hao; Varun Khurana; Dhananjay Pal
Journal:  J Control Release       Date:  2015-10-09       Impact factor: 9.776

Review 5.  Vector engineering, strategies and targets in cancer gene therapy.

Authors:  Vijayata Singh; Nusrat Khan; Giridhara R Jayandharan
Journal:  Cancer Gene Ther       Date:  2021-04-15       Impact factor: 5.987

Review 6.  Seek and destroy: targeted adeno-associated viruses for gene delivery to hepatocellular carcinoma.

Authors:  Bijay Dhungel; Aparna Jayachandran; Christopher J Layton; Jason C Steel
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

7.  Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model.

Authors:  Matheus Hw Crommentuijn; Rami Kantar; David P Noske; W Peter Vandertop; Christian E Badr; Thomas Würdinger; Casey A Maguire; Bakhos A Tannous
Journal:  Mol Ther Oncolytics       Date:  2016-06-22       Impact factor: 7.200

8.  Construction of a plasmid for human brain-derived neurotrophic factor and its effect on retinal pigment epithelial cell viability.

Authors:  Bo-Jing Yan; Zhi-Zhong Wu; Wei-Hua Chong; Gen-Lin Li
Journal:  Neural Regen Res       Date:  2016-12       Impact factor: 5.135

Review 9.  Current applications and future prospects of nanomaterials in tumor therapy.

Authors:  Yu Huang; Chao-Qiang Fan; Hui Dong; Su-Min Wang; Xiao-Chao Yang; Shi-Ming Yang
Journal:  Int J Nanomedicine       Date:  2017-03-07

10.  H1/pHGFK1 nanoparticles exert anti-tumoural and radiosensitising effects by inhibition of MET in glioblastoma.

Authors:  Wenyan Zhang; Rui Duan; Jian Zhang; William K C Cheung; Xiaoge Gao; Raymond Zhang; Qing Zhang; Mengxue Wei; Gang Wang; Qian Zhang; Peng-Jin Mei; Hong-Lin Chen; Hsiangfu Kung; Marie C Lin; Zan Shen; Junnian Zheng; Longzhen Zhang; Hong Yao
Journal:  Br J Cancer       Date:  2018-01-18       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.